Atherosclerosis protection mechanism of omega-3 polyunsaturated fatty acid metabolites

Home > Archive>Volume 28, Issue 6, 2020 >461-467

Atherosclerosis protection mechanism of omega-3 polyunsaturated fatty acid metabolites
DOI:
                        
                    
CSTR:
                        [cstr]
                    
Author:
                        ZHAO YinjiaoZHAO Yinjiao
Key Laboratory of Metabolic Cardiovascular Disease & Department of Physiology and Pathophysiology, Tianjin Medical University, Tianjin 300070, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
YAO LiuYAO Liu
Key Laboratory of Metabolic Cardiovascular Disease & Department of Physiology and Pathophysiology, Tianjin Medical University, Tianjin 300070, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
ZHANG XuZHANG Xu
Key Laboratory of Metabolic Cardiovascular Disease & Department of Physiology and Pathophysiology, Tianjin Medical University, Tianjin 300070, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
ZHU YiZHU Yi
Key Laboratory of Metabolic Cardiovascular Disease & Department of Physiology and Pathophysiology, Tianjin Medical University, Tianjin 300070, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site

                    
Affiliation:Key Laboratory of Metabolic Cardiovascular Disease & Department of Physiology and Pathophysiology, Tianjin Medical University, Tianjin 300070, China)
Clc Number:R363；R5
Fund Project:

Article

Figures

Metrics

Reference [49]

Related [20]

Cited by

Materials

Comments

Abstract:

Atherosclerosis is a chronic inflammatory response caused by activation of endothelial cells, lipid deposition, and other relative pathogenic factor. Omega-3 polyunsaturated fatty acids (n-3 PUFA) play an important protective role in atherosclerosis, however, the underlying mechanism remains unclear. n-3 PUFA could produce different biological active eicosanoid metabolites by cyclooxygenase, lipoxygenase and cytochrome P450 oxidase, alternatively, it competes with arachidonic acid for the common metabolic enzymes to regulate the levels of arachidonic acid-derived eicosanoid metabolites. Based on the metabolic perspective, this paper systematically discusses the atherosclerosis protective mechanism that n-3 PUFA exerts by affecting the eicosanoid metabolism profile.

Key words:atherosclerosis; omega-3 polyunsaturated fatty acids; metabolites; cardiovascular disease

Reference

[1] 赵战芝, 姜志胜.我国动脉粥样硬化基础研究几个热点领域的新进展.中国动脉硬化杂志, 9,7:645-654.

[2] Lavie CJ, Milani RV, Mehra MR, et al.Omega-3 polyunsaturated fatty acids and cardiovascular diseases.J Am Coll Cardiol, 9,4:585-594.

[3] Yam D, Bott-Kanner G, Genin I, et al.The effect of omega-3 fatty acids on risk factors for cardiovascular diseases.Harefuah, 1,0:1156-1158.

[4] Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction:results of the GISSI-Prevenzione trial.Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico .Lancet, 9,4:447-455.

[5] Yokoyama M, Origasa H, Matsuzaki M, et al.Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS):a randomised open-label, blinded endpoint analysis.Lancet, 7,9:1090-1098.

[6] Tavazzi L, Maggioni AP, Marchioli R, et al.Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial):a randomised, double-blind, placebo-controlled trial.Lancet, 8,2:1223-1230.

[7] Einvik G, Klemsdal TO, Sandvik L, et al.A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk.Eur J Cardiovasc Prev Rehabil, 0,7(5):588-592.

[8] Galan P, Kesse-Guyot E, Czernichow S, et al.Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases:a randomised placebo controlled trial.BMJ, 0,1:c6273.

[9] Rauch B, Schiele R, Schneider S, et al.Omega, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction.Circulation, 0,2:2152-2159.

[10] Kromhout D, Giltay EJ, Geleijnse JM, et al.n-3 Fatty acids and cardiovascular events after myocardial infarction.N Engl J Med, 0,3:2015-2026.

[11] Bosch J, Gerstein HC, Dagenais GR, et al.n-3 Fatty acids and cardiovascular outcomes in patients with dysglycemia.N Engl J Med, 2,7:309-318.

[12] Roncaglioni MC.n-3 Fatty acids in patients with multiple cardiovascular risk factors.N Engl J Med, 3,8:2146.

[13] Aung T, Halsey J, Kromhout D, et al.Associations of omega-3 fatty acid supplement use with cardiovascular disease risks meta-analysis of 10 trials involving 77917 individuals.JAMA Cardiol, 8,3:225-233.

[14] Bowman L, Mafham M, Wallendszus K, et al.Effects of n-3 fatty acid supplements in diabetes mellitus.N Engl J Med, 8,9:1540-1550.

[15] Manson JE, Cook NR, Lee IM, et al.Marine n-3 fatty acids and prevention of cardiovascular disease and cancer.N Engl J Med, 9,0:23-32.

[16] Bhatt DL, Steg PG, Miller M, et al.Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.N Engl J Med, 9,0:11-22.

[17] Kuehl FA Jr, Egan RW.Prostaglandins, arachidonic acid, and inflammation.Science, 0,0(4473):978-984.

[18] 曹野, 王伟琼, 陈晨, 等.ω-3多不饱和脂肪酸的结构、代谢及与动脉粥样硬化的关系.中国动脉硬化杂志, 8,6:633-643.

[19] Ferrer MD, Busquets-Cortes C, Capo X, et al.Cyclooxygenase-2 inhibitors as a therapeutic target in inflammatory diseases.Curr Med Chem, 9,6:3225-3241.

[20] Nishikawa M, Hishinuma T, Nagata K, et al.Effects of eicosapentaenoic acid (EPA) on prostacyclin production in diabetics:GC/MS analysis of PGI2 and PGI3 levels.Methods Find Exp Clin Pharmacol, 7,9:429-433.

[21] Poeckel D, Funk CD.The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease.Cardiovasc Res, 0,6:243-253.

[22] Bck M.Leukotriene signaling in atherosclerosis and ischemia.Cardiovasc Drugs Ther, 9,3:41-48.

[23] Bck M.Omega-3 fatty acids in atherosclerosis and coronary artery disease.Future Sci OA, 7,3:FSO236.

[24] Bck M, Powell WS, Dahlen SE, et al.Update on leukotriene, lipoxin and oxoeicosanoid receptors:IUPHAR Review 7.Br J Pharmacol, 4,1(15):3551-3574.

[25] Leiria LO, Wang CH, Lynes MD, et al.12-Lipoxygenase regulates cold adaptation and glucose metabolism by producing the omega-3 lipid 12-HEPE from brown fat.Cell Metab, 9,0:768-783.

[26] Tsunomori M, Fujimoto Y, Muta E, et al.15-Hydroperoxyeicosapentaenoic acid inhibits arachidonic acid metabolism in rabbit platelets more potently than eicosapentaenoic acid.Biochim Biophys Acta, 6,0:171-176.

[27] Manega CM, Fiorelli S, Porro B, et al.12(S)-Hydroxyeicosatetraenoic acid downregulates monocyte-derived macrophage efferocytosis:new insights in atherosclerosis.Pharmacol Res, 9,4:336-342.

[28] Kotla S, Singh NK, Traylor JG, et al.ROS-dependent Syk and Pyk2-mediated STAT1 activation is required for 15(S)-hydroxyeicosatetraenoic acid-induced CD36 expression and foam cell formation.Free Radic Biol Med, 4,6:147-162.

[29] Schuchardt JP, Ostermann AI, Stork L, et al.Effect of DHA supplementation on oxylipin levels in plasma and immune cell stimulated blood.Prostaglandins Leukot Essent Fatty Acids, 7,1:76-87.

[30] Croset M, Sala A, Folco G, et al.Inhibition by lipoxygenase products of TXA2-like responses of platelets and vascular smooth muscle.14-Hydroxy from 22:6n-3 is more potent than 12-HETE.Biochem Pharmacol, 8,7:1275-1280.

[31] Jung F, Schulz C, Blaschke F, et al.Effect of cytochrome P450-dependent epoxyeicosanoids on Ristocetin-induced thrombocyte aggregation.Clin Hemorheol Microcirc, 2,2:403-416.

[32] Liu Y, Fang X, Zhang X, et al.Metabolic profiling of murine plasma reveals eicosapentaenoic acid metabolites protecting against endothelial activation and atherosclerosis.Br J Pharmacol, 8,5:1190-1204.

[33] Bck M, Yurdagul A Jr, Tabas I, et al.Inflammation and its resolution in atherosclerosis:mediators and therapeutic opportunities.Nat Rev Cardiol, 9,6:389-406.

[34] Elajami TK, Colas RA, Dalli J, et al.Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling.FASEB J, 6,0:2792-2801.

[35] Arita M, Ohira T, Sun YP, et al.Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation.J Immunol, 7,8:3912-3917.

[36] Laguna-Fernandez A, Checa A, Carracedo M, et al.ERV1/ChemR23 signaling protects against atherosclerosis by modifying oxidized low-density lipoprotein uptake and phagocytosis in macrophages.Circulation, 8,8:1693-1705.

[37] Spite M, Claria J, Serhan CN.Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases.Cell Metab, 4,9:21-36.

[38] Fredman G, Hellmann J, Proto JD, et al.An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques.Nat Commun, 6,7:12859.

[39] Kasikara C, Doran AC, Cai BS, et al.The role of non-resolving inflammation in atherosclerosis.J Clin Invest, 8,8:2713-2723.

[40] Yang J, Schmelzer K, Georgi K, et al.Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry.Anal Chem, 9,1:8085-8093.

[41] Strassburg K, Huijbrechts AML, Kortekaas KA, et al.Quantitative profiling of oxylipins through comprehensive LC-MS/MS analysis:application in cardiac surgery.Anal Bioanal Chem, 2,4:1413-1426.

[42] Kortz L, Dorow J, Becker S, et al.Fast liquid chromatography-quadrupole linear ion trap-mass spectrometry analysis of polyunsaturated fatty acids and eicosanoids in human plasma.J Chromatogr B Analyt Technol Biomed Life Sci, 3,7:209-213.

[43] Gladine C, Newman JW, Durand T, et al.Lipid profiling following intake of the omega 3 fatty acid DHA identifies the peroxidized metabolites F4-neuroprostanes as the best predictors of atherosclerosis prevention.PLoS One, 4,9:e89393.

[44] Zhang X, Yang N, Ai D, et al.Systematic metabolomic analysis of eicosanoids after omega-3 polyunsaturated fatty acid supplementation by a highly specific liquid chromatography-tandem mass spectrometry-based method.J Proteome Res, 5,4:1843-1853.

[45] Bao Q, Liu Y, Song H, et al.Spectrum evaluation-assisted eicosanoid metabolomics for global eicosanoid profiling in human vascular endothelial cells.Clin Exp Pharmacol Physiol, 8,5:98-108.

[46] Quehenberger O, Dahlberg-Wright S, Jiang J, et al.Quantitative determination of esterified eicosanoids and related oxygenated metabolites after base hydrolysis.J Lipid Res, 8,9:2436-2445.

[47] Yuan ZX, Majchrzak-Hong S, Keyes GS, et al.Lipidomic profiling of targeted oxylipins with ultra-performance liquid chromatography-tandem mass spectrometry.Anal Bioanal Chem, 8,0:6009-6029.

[48] Kutzner L, Rund KM, Ostermann AI, et al.Development of an optimized LC-MS method for the detection of specialized pro-resolving mediators in biological samples.Front Pharmacol, 9,0:169.

[49] Chocholouskova M, Jirasko R, Vrana D, et al.Reversed phase UHPLC/ESI-MS determination of oxylipins in human plasma:a case study of female breast cancer.Anal Bioanal Chem, 9,1:1239-1251.

Get Citation

ZHAO Yinjiao, YAO Liu, ZHANG Xu, ZHU Yi. Atherosclerosis protection mechanism of omega-3 polyunsaturated fatty acid metabolites[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2020,28(6):461-467.

Copy

Article Metrics

Abstract:747
PDF: 741
HTML: 0
Cited by: 0

History

Received:December 17,2019
Revised:January 03,2020
Adopted:
Online: May 22,2020
Published:

Policies & Instructions

Get Citation

Share

Article Metrics

History

Article QR Code